Market Cap
$187.7M
NKTX
Nkarta, Inc.
$2.56 ▼ -0.20%
Prev close $2.56Market cap$187.7M
ConsensusStrong Buy
12-mo target$10.83 (+324.0%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)21 New Institutional Positions11 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on NKTX right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (92%)
Inst. Holders
50 funds
Inst. Value
$108.7M
Inst. Activity
21 buys / 11 sells
Insider Activity
$0.00 buy / $4.8K sell
Insider Net $
-$4.8K
Social Sentiment
78° Bullish
SEC Reports
6
Press Releases
2
Price chart 30d -7.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 8, 2026 other
Aug 11, 2026 SEC Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clini
Nkarta reported Q2 2026 net loss of $0.54 per share, significantly missing the consensus estimate of -$0.36 per share. T
8-K — Impact 6/10
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
6,300,212 shares ($17.8M)
Jun 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
1,177,652 shares ($3.3M)
Jun 18, 2026 Insider
HASTINGS PAUL J sold 1,776 shares
Chief Executive Officer @ $2.71 ($4.8K)
Jun 10, 2026 Insider
Thedinga Angela was granted 37,000 shares
Director
Jun 10, 2026 Insider
May 12, 2026 SEC PATTERSON LEONE D was granted 37,000 shares
Director
Nkarta reported Q1 2026 EPS of -$0.37, a slight miss vs consensus of -$0.36, with no revenue. The company highlighted FD
PRESS-RELEASE — Impact 4/10
Analyst ratings buy % +8.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
92% rate it Buy or better · 13 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 14, 2026 | Stifel | MAINTAIN | Buy | 54% |
| Aug 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| May 13, 2026 | Needham | REITERATE | Buy | 50% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Aug 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Jul 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Jun 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Feb 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% |
Price targets
Where 6 covering analysts think NKTX trades over the next 12 months.
$10.83 +324.0% upside Strong Buy
Current$2.56 Low$9.00 Median$10.50 High$14.00 6 analysts
$9.00$14.00
Analyst rating Strong Buy· 1.1/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
78°
Bullish
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 1 bullish, 4 bearish, 0 mixed, 1 neutral · avg impact 6.0/10.Plus 2 press releases.
BEARISH8-K6/10
Nkarta reported Q2 2026 net loss of $0.54 per share, significantly missing the consensus estimate of
Aug 11, 2026
NEUTRALPRESS-RELEASE4/10
Nkarta reported Q1 2026 EPS of -$0.37, a slight miss vs consensus of -$0.36, with no revenue. The co
May 12, 2026
BEARISHEFFECT7/10
Nkarta, Inc. (NKTX) has an S-3 shelf registration that became effective on April 3, 2026, allowing t
Apr 6, 2026
BEARISH8-K6/10
Nkarta, Inc. announced an at-the-market (ATM) offering program allowing it to sell up to $100 millio
Mar 26, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 8, 2026
other
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing enginee
Aug 10, 2026
earnings
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineer
Aug 10, 2026
earnings_calendar
NKTX Q2 2026 Earnings Scheduled — 2026-08-10
Aug 6, 2026
earnings_calendar
NKTX Q2 2026 Earnings Scheduled — 2026-08-06
Jun 26, 2026
other
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
At 2 p.m. ET on Tuesday, June 30th, Nkarta President Nadir Mahmood will take part in a fireside at the H.C. Wainwright Cell Therapy Virtual Conference
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.38 | $-0.46–$-0.34 | -32.2% | -3.6% | 0↑ 1↓ | $0.0B | 3 |
| Next Q | $-0.40 | $-0.48–$-0.35 | -8.1% | -5.3% | 0↑ 1↓ | $0.0B | 3 |
| Current FY | $-1.71 | $-1.86–$-1.61 | -21.0% | -15.3% | 0↑ 2↓ | $0.0B | 3 |
| Next FY | $-1.75 | $-2.26–$-1.45 | -2.7% | -6.3% | 0↑ 2↓ | $0.0B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.383 | — |
| 7d ago | $-0.370 | -0.013 |
| 30d ago | $-0.370 | -0.013 |
| 60d ago | $-0.385 | +0.002 |
| 90d ago | $-0.385 | +0.002 |
Institutional ownership
Which big funds own NKTX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $108.7M total value (38,425,469 shares) as of 2026-Q2. Top holders: RA, BlackRock,, VANGUARD. Net buying activity: 21 institutions added/increased vs 11 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10,805,129 | $30.6M | 28.1% | — |
| BlackRock, Inc. | 6,300,212 | $17.8M | 16.4% | ADD +39.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,226,415 | $6.3M | 5.8% | — |
| CITADEL ADVISORS LLC | 2,174,745 | $6.2M | 5.7% | — |
| TWO SIGMA INVESTMENTS, LP | 1,873,293 | $5.3M | 4.9% | — |
| WASATCH ADVISORS LP | 1,577,847 | $4.5M | 4.1% | — |
| STATE STREET CORP | 1,286,109 | $3.6M | 3.3% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 1,285,507 | $3.6M | 3.3% | — |
| RENAISSANCE TECHNOLOGIES LLC | 1,177,652 | $3.3M | 3.1% | TRIM -32.0% |
| AQR CAPITAL MANAGEMENT LLC | 1,054,251 | $3.0M | 2.7% | ADD +86.8% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 4,508,473 | 6,300,212 | +39.7% | $17.8M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,732,372 | 1,177,652 | -32.0% | $3.3M |
| PANAGORA ASSET MANAGEMENT INC | DOUBLED | 284,210 | 583,249 | +105.2% | $1.7M |
| Alyeska Investment Group, L.P. | NEAR_EXIT | 2,084,840 | 484,840 | -76.7% | $1.4M |
| DIMENSIONAL FUND ADVISORS LP | ADD | 346,593 | 483,211 | +39.4% | $1.4M |
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 145,688 | 323,659 | +122.2% | $916.0K |
| IEQ CAPITAL, LLC | ADD | 102,849 | 177,038 | +72.1% | $501.0K |
| D. E. Shaw & Co., Inc. | TRIM | 356,932 | 162,509 | -54.5% | $459.9K |
| Point72 Asset Management, L.P. | ADD | 60,348 | 106,806 | +77.0% | $302.3K |
| Man Group plc | TRIM | 152,622 | 100,047 | -34.4% | $283.1K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 9 transactions. Net -$4.8K — $0.00 bought, $4.8K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 18, 2026 | HASTINGS PAUL J | Chief Executive Officer | SELL | 1,776 | $2.71 | $4.8K |
| Jun 10, 2026 | Thedinga Angela | Director | AWARD | 37,000 | — | — |
| Jun 10, 2026 | PATTERSON LEONE D | Director | AWARD | 37,000 | — | — |
| Jun 10, 2026 | Dybbs Michael | Director | AWARD | 37,000 | — | — |
| Jun 10, 2026 | Scheiner Zachary | Director | AWARD | 37,000 | — | — |
| Jun 10, 2026 | Vratsanos George | Director | AWARD | 37,000 | — | — |
| Jun 10, 2026 | George Simeon | Director | AWARD | 37,000 | — | — |
| Jun 10, 2026 | Behbahani Ali | Director | AWARD | 37,000 | — | — |
| Jun 10, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | AWARD | 37,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for NKTX.
Shares short
3,506,533
Settlement Sep 15, 2026
Change vs prior
+2.0%
Semi-monthly cycle
Days to cover
5.5
At avg daily volume
Of shares outstanding
≈4.9%
Estimate — not % of float
All NKTX filing & press-release reports (8)
- 8-K reportAug 11, 2026
- PRESS-RELEASE reportMay 12, 2026
- PRESS-RELEASE reportApr 15, 2026
- EFFECT reportApr 6, 2026
- 8-K reportMar 26, 2026
- S-3 reportMar 25, 2026
- PRESS-RELEASE reportMar 25, 2026
- INST-CLUSTER reportFeb 28, 2026